Skip to main content
Erschienen in: Documenta Ophthalmologica 2/2017

25.07.2017 | Original Research Article

Safety of intravitreal clindamycin in albino rabbit eyes

verfasst von: Zohar Habot-Wilner, Orit Mazza, Jonathan Shahar, Amir Massarweh, Irit Mann, Anat Loewenstein, Ido Perlman

Erschienen in: Documenta Ophthalmologica | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To study the potential toxic effects of intravitreal clindamycin on the retina of albino rabbits, by assessing functional and morphological retinal changes.

Methods

Eight albino rabbits were included in the study. In each rabbit, 1 mg/0.1 ml clindamycin was injected into the vitreous of the right (experimental) eye, and 0.1 ml saline was injected into the vitreous of the left (control) eye. The electroretinogram (ERG) was recorded before injection, 3 days, 1, 2, and 4 weeks post-injection. The visual evoked potential (VEP) was recorded 4 weeks post-injection. Clinical examination was conducted at all time points. The eyes were enucleated at the termination of the follow-up period in order to prepare the retinas for histology in order to assess retinal structure.

Results

ERG and VEP responses that were recorded from the experimental eye at different times following intravitreal clindamycin injection were very similar to the corresponding responses that were recorded from the control eyes. Clinical examination was normal in all eyes, and no histological damage was observed.

Conclusions

Intravitreal injection of 1 mg clindamycin does not cause functional or morphological signs of retinal toxicity in albino rabbits, during a period of 4 weeks post-injection. These findings support the clinical use of 1 mg intravitreal clindamycin.
Literatur
1.
Zurück zum Zitat Holland GN (2003) Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 136:973–988CrossRefPubMed Holland GN (2003) Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 136:973–988CrossRefPubMed
2.
Zurück zum Zitat Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG (2009) Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis 15:878–884CrossRef Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG (2009) Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis 15:878–884CrossRef
4.
Zurück zum Zitat Tate GW Jr, Martin RG (1977) Clindamycin in the treatment of human ocular toxoplasmosis. Can J Ophthalmol 12:188–195PubMed Tate GW Jr, Martin RG (1977) Clindamycin in the treatment of human ocular toxoplasmosis. Can J Ophthalmol 12:188–195PubMed
5.
Zurück zum Zitat Tabbara KF, O’Connor GR (1980) Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. Ophthalmology 87:129–134CrossRefPubMed Tabbara KF, O’Connor GR (1980) Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. Ophthalmology 87:129–134CrossRefPubMed
6.
Zurück zum Zitat Guldsten H (1983) Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol 61:51–57CrossRef Guldsten H (1983) Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol 61:51–57CrossRef
7.
Zurück zum Zitat Lakhanpal V, Schocket SS, Nirankari VS (1983) Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am J Ophthalmol 95:605–613CrossRefPubMed Lakhanpal V, Schocket SS, Nirankari VS (1983) Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am J Ophthalmol 95:605–613CrossRefPubMed
8.
Zurück zum Zitat Rothova A, Meenken C, Buitenhuis HJ et al (1993) Therapy for ocular toxoplasmosis. Am J Ophthalmol 115:517–523CrossRefPubMed Rothova A, Meenken C, Buitenhuis HJ et al (1993) Therapy for ocular toxoplasmosis. Am J Ophthalmol 115:517–523CrossRefPubMed
9.
Zurück zum Zitat Tabbara KF, Dy-Liacco J, Nozik RA, O’Connor GR, Blackman HJ (1979) Clindamycin in chronic toxoplasmosis: effect of periocular injections on recoverability of organisms from healed lesions in the rabbit eye. Arch Ophthalmol 97:542–544CrossRefPubMed Tabbara KF, Dy-Liacco J, Nozik RA, O’Connor GR, Blackman HJ (1979) Clindamycin in chronic toxoplasmosis: effect of periocular injections on recoverability of organisms from healed lesions in the rabbit eye. Arch Ophthalmol 97:542–544CrossRefPubMed
10.
Zurück zum Zitat Ferguson JG Jr (1981) Clindamycin therapy for toxoplasmosis. Ann Ophthalmol 13:95–100PubMed Ferguson JG Jr (1981) Clindamycin therapy for toxoplasmosis. Ann Ophthalmol 13:95–100PubMed
11.
Zurück zum Zitat Martinez CE, Zhang D, Conway MD, Peyman GA (1998) Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol 22:85–88CrossRefPubMed Martinez CE, Zhang D, Conway MD, Peyman GA (1998) Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol 22:85–88CrossRefPubMed
12.
Zurück zum Zitat Kishore K, Conway MD, Peyman GA (2001) Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers 32:183–192PubMed Kishore K, Conway MD, Peyman GA (2001) Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers 32:183–192PubMed
13.
Zurück zum Zitat Sobrin L, Kump LI, Foster CS (2007) Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina 27:952–957CrossRefPubMed Sobrin L, Kump LI, Foster CS (2007) Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina 27:952–957CrossRefPubMed
14.
Zurück zum Zitat Wong R, dell’Omo R, Marino M, Hussein B, Okhravi N, Pavesio CE (2009) Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin. Int Ophthalmol 29:195–198CrossRefPubMed Wong R, dell’Omo R, Marino M, Hussein B, Okhravi N, Pavesio CE (2009) Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin. Int Ophthalmol 29:195–198CrossRefPubMed
15.
Zurück zum Zitat Lasave AF, Díaz-Llopis M, Muccioli C, Belfort R Jr, Arevalo JF (2010) Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 117:1831–1838CrossRefPubMed Lasave AF, Díaz-Llopis M, Muccioli C, Belfort R Jr, Arevalo JF (2010) Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 117:1831–1838CrossRefPubMed
16.
Zurück zum Zitat Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA (2011) Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 118:134–141CrossRefPubMed Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA (2011) Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 118:134–141CrossRefPubMed
17.
Zurück zum Zitat Baharivand N, Mahdavifard A, Fouladi RF (2013) Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol 33:39–46CrossRefPubMed Baharivand N, Mahdavifard A, Fouladi RF (2013) Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol 33:39–46CrossRefPubMed
18.
Zurück zum Zitat Zamora YF, Arantes T, Reis FA, Garcia CR, Saraceno JJ, Belfort R Jr, Muccioli C (2015) Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone. Arq Bras Oftalmol 78:216–219CrossRefPubMed Zamora YF, Arantes T, Reis FA, Garcia CR, Saraceno JJ, Belfort R Jr, Muccioli C (2015) Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone. Arq Bras Oftalmol 78:216–219CrossRefPubMed
19.
Zurück zum Zitat Kim P, Younan N, Coroneo MT (2002) Hypersensitivity reaction to intravitreal clindamycin therapy. Clin Experiment Ophthalmol 30:147–148CrossRefPubMed Kim P, Younan N, Coroneo MT (2002) Hypersensitivity reaction to intravitreal clindamycin therapy. Clin Experiment Ophthalmol 30:147–148CrossRefPubMed
20.
Zurück zum Zitat Paque JT, Peyman GA (1974) Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic Surg 5:34–39 Paque JT, Peyman GA (1974) Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic Surg 5:34–39
21.
Zurück zum Zitat Stainer GA, Peyman GA, Meisels H, Fishman G (1977) Toxicity of selected antibiotics in vitreous replacement fluid. Ann Ophthalmol 9:615–618PubMed Stainer GA, Peyman GA, Meisels H, Fishman G (1977) Toxicity of selected antibiotics in vitreous replacement fluid. Ann Ophthalmol 9:615–618PubMed
22.
Zurück zum Zitat Loewenstein A, Zemel E, Lazar M, Perlman I (1993) Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Invest Ophthalmol Vis Sci 34:3466–3476PubMed Loewenstein A, Zemel E, Lazar M, Perlman I (1993) Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Invest Ophthalmol Vis Sci 34:3466–3476PubMed
23.
Zurück zum Zitat McCulloch DL, Marmor M, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M (2015) ISCEV standard for full-field electroretinography (2015 update). Doc Ophthalmol 130:1–12CrossRefPubMed McCulloch DL, Marmor M, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M (2015) ISCEV standard for full-field electroretinography (2015 update). Doc Ophthalmol 130:1–12CrossRefPubMed
24.
Zurück zum Zitat Fulton AB, Hansen RM (1988) Scotopic stimulus/response relations of the b-wave of the electroretinogram. Doc Ophthalmol 68:193–304CrossRef Fulton AB, Hansen RM (1988) Scotopic stimulus/response relations of the b-wave of the electroretinogram. Doc Ophthalmol 68:193–304CrossRef
25.
Zurück zum Zitat Arden GB, Carter RM, Hogg CR, Powell DJ, Ernst WJK, Clover GM, Lyness AL, Quinlan MP (1983) A modified ERG technique and the results obtained in X-lined retinitis pigmentosa. Br J Ophthalmol 67:419–430CrossRefPubMedPubMedCentral Arden GB, Carter RM, Hogg CR, Powell DJ, Ernst WJK, Clover GM, Lyness AL, Quinlan MP (1983) A modified ERG technique and the results obtained in X-lined retinitis pigmentosa. Br J Ophthalmol 67:419–430CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Peachey NS, Alexander KR, Fishman GA (1989) The luminance-response function of the dark-adapted human electroretinogram. Vision Res 29:263–270CrossRefPubMed Peachey NS, Alexander KR, Fishman GA (1989) The luminance-response function of the dark-adapted human electroretinogram. Vision Res 29:263–270CrossRefPubMed
27.
Zurück zum Zitat Severns ML, Johnson MA (1993) The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data. Doc Ophthalmol 85:135–150CrossRefPubMed Severns ML, Johnson MA (1993) The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data. Doc Ophthalmol 85:135–150CrossRefPubMed
28.
Zurück zum Zitat Bresnick GH, Palta M (1987) Oscillatory potential amplitudes relation to severity of diabetic retinopathy. Arch Ophthalmol 105:929–933CrossRefPubMed Bresnick GH, Palta M (1987) Oscillatory potential amplitudes relation to severity of diabetic retinopathy. Arch Ophthalmol 105:929–933CrossRefPubMed
29.
Zurück zum Zitat Perlman I (2009) Testing retinal toxicity of drugs in animal models using electrophysiological and morphological techniques. Doc Ophthalmol 118:3–28CrossRefPubMed Perlman I (2009) Testing retinal toxicity of drugs in animal models using electrophysiological and morphological techniques. Doc Ophthalmol 118:3–28CrossRefPubMed
30.
Zurück zum Zitat Perlman I (1983) Relationship between the amplitudes of the b wave and the a wave as a useful index for evaluating the electroretinogram. Br J Ophthalmol 67:443–448CrossRefPubMedPubMedCentral Perlman I (1983) Relationship between the amplitudes of the b wave and the a wave as a useful index for evaluating the electroretinogram. Br J Ophthalmol 67:443–448CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wachtmeister L (1998) Oscillatory potentials in the retina: what do they reveal. Prog Retina Eye Res 17:485–521CrossRef Wachtmeister L (1998) Oscillatory potentials in the retina: what do they reveal. Prog Retina Eye Res 17:485–521CrossRef
32.
Zurück zum Zitat Peyman GA, Charles HC, Liu KR, Khoobehi B, Niesman M (1988) Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol 12:175–182CrossRefPubMed Peyman GA, Charles HC, Liu KR, Khoobehi B, Niesman M (1988) Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol 12:175–182CrossRefPubMed
33.
Zurück zum Zitat Del Amo EM, Urtti A (2015) Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res 137:111–124CrossRefPubMed Del Amo EM, Urtti A (2015) Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res 137:111–124CrossRefPubMed
Metadaten
Titel
Safety of intravitreal clindamycin in albino rabbit eyes
verfasst von
Zohar Habot-Wilner
Orit Mazza
Jonathan Shahar
Amir Massarweh
Irit Mann
Anat Loewenstein
Ido Perlman
Publikationsdatum
25.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Documenta Ophthalmologica / Ausgabe 2/2017
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-017-9599-5

Weitere Artikel der Ausgabe 2/2017

Documenta Ophthalmologica 2/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.